Biotechnology: analysis of 11 November 2026

Back to the Chronology · Current news in this section

Photo from PepGen soars on promising early data for muscular dystrophy drug, BioPharma Dive

Analysis

Gene editing and gene therapy hit milestones and warnings this week, as the FDA flags a GLP-1 eye risk, dealmaking continues and US–China biotech rivalry sharpens.

This week's biotech news mixes clinical milestones with new risks. Beam's base editing therapy for sickle cell met its goal in a pivotal trial, and Vir's hepatitis D drug and PepGen's muscular dystrophy drug reported positive data, while a long-debated cancer risk from gene therapy has now appeared. The FDA warned that GLP-1 weight-loss drugs may carry a rare risk of vision loss, and experts fear the focus on these drugs could strain insulin supply. The FDA approved Bayer's new kind of blood thinner, but Novartis's Lp(a) heart drug failed. Deals continue: Argenx agreed acquisitions worth up to $1.15 billion, Silence was bought for $1.3 billion, and Oyster raised $60 million. Geopolitics is also present: China plans a ban on biotech exports, WuXi AppTec's shares jumped after a Pentagon blacklist reversal, and BIO set out a plan to keep the US in the lead.

Key developments

  • Gene editing and gene therapy. Beam's base editing therapy for sickle cell hit its goal in a pivotal trial, while gene therapy's long-debated cancer risk has now materialised. 422
  • Trial results. Vir's hepatitis D drug succeeded in a pivotal study and PepGen soared on early muscular dystrophy data, but Novartis's Lp(a) drug failed. 19230
  • FDA decisions. The FDA warned GLP-1 drugs may cause a rare vision-loss condition and approved Bayer's novel drug to reduce stroke recurrence. 1101617
  • Deals and funding. Argenx agreed acquisitions worth up to $1.15 billion, Silence was acquired for $1.3 billion, and London's Oyster raised $60 million for tau drugs. 9203512
  • US–China rivalry. China plans a ban on biotech exports, WuXi AppTec's shares jumped after a Pentagon blacklist reversal, and BIO unveiled a plan for US leadership. 381413
  • Drug pricing and supply. BIO joined a legal fight against a Medicare pilot linking drug prices to other countries, and experts warn weight-loss drugs may squeeze insulin supply. 2911

Themes

  • AI in drug discovery. New AI models are speeding protein design, but recent heart drug failures are a reason for scepticism about AI hype. 243328
  • Manufacturing costs. Automation could lower cell therapy costs, and scaling from Phase II to Phase III takes more than capacity. 826

What to watch

  • FDA review of Beam's sickle cell therapy. 4
  • Details of China's biotech export ban. 38
  • Label changes for GLP-1 drugs. 1
Stories this analysis is based on (23)
  1. FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss Ars Technica
  2. PepGen soars on promising early data for muscular dystrophy drug BioPharma Dive
  3. Beam’s base editing therapy for sickle cell hits goal in pivotal trial BioPharma Dive
  4. Automation a Path to Lower Cell Therapy Costs GEN (Genetic Engineering & Biotechnology News)
  5. Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition GEN (Genetic Engineering & Biotechnology News)
  6. STAT+: GLP-1s are given an FDA warning for rare eye condition risk STAT Biotech
  7. Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn The Guardian US
  8. London biotech Oyster harvests $60M for tau-targeting brain drugs BioPharma Dive
  9. BIO unveils plan for US to remain biotech’s ‘global leader’ BioPharma Dive
  10. Chinese biotech giant WuXi AppTec’s shares jump after Pentagon blacklist reversal South China Morning Post
  11. Bayer wins FDA nod for a new kind of blood thinner BioPharma Dive
  12. STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke STAT Biotech
  13. Vir hepatitis D drug succeeds in first pivotal study BioPharma Dive
  14. Argenx to buy peptide platform in potentially billion-dollar deal BioPharma Dive
  15. STAT+: Gene therapy’s long-debated cancer risk materializes STAT Biotech
  16. New AI Models Are Turbo-Charging Protein Design GEN (Genetic Engineering & Biotechnology News)
  17. Translating Phase II success into Phase III readiness takes more than scale BioPharma Dive
  18. STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype STAT Biotech
  19. STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries STAT Biotech
  20. STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy STAT Biotech
  21. De novo design of proteases Nature Biotechnology
  22. Silence snapped up for $1.3 billion Nature Biotechnology
  23. China plans ban on biotech exports Nature Biotechnology

Written by Claude (Anthropic), based on 45 recent headlines and excerpts in this section, Nov 11. AI analysis can misread or miss things: the numbers link to the original reporting, which is the authority.